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Abstract
The ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) multigene family contains five members. NPP1-3 are type II
transmembrane metalloenzymes characterized by a similar modular structure composed of a short intracellular domain, a single
transmembrane domain and an extracellular domain containing a conserved catalytic site. The short intracellular domain of NPP1 has a
basolateral membrane-targeting signal while NPP3 is targeted to the apical surface of polarized cells. NPP4-5 detected by database searches
have a predicted type I membrane orientation but have not yet been functionally characterized.
E-NPPs have been detected in almost all tissues often confined to specific substructures or cell types. In some cell types, NPP1 expression
is constitutive or can be induced by TGF-h and glucocorticoids, but the signal transduction pathways that control expression are poorly
documented.
NPP1-3 have a broad substrate specificity which may reflect their role in a host of physiological and biochemical processes including
bone mineralization, calcification of ligaments and joint capsules, modulation of purinergic receptor signalling, nucleotide recycling, and cell
motility. Abnormal NPP expression is involved in pathological mineralization, crystal depositions in joints, invasion and metastasis of cancer
cells, and type 2 diabetes.
In this review we summarize the present knowledge on the structure and the physiological and biochemical functions of E-NPP and their
contribution to the pathogenesis of diseases.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Extracellular nucleotide hydrolysis was originally be-
lieved to be a straightforward process in which individual
enzymes hydrolyze ATP (ecto-ATPase), ADP (ecto-ATPase,
ecto-ATPDase) and AMP (ecto-5V-nucleotidase) but recent
work has revealed a more complex picture involving several
families of ecto-nucleotidases. These enzymes appear to
have multiple roles in extracellular nucleotide metabolism
and in the regulation of nucleotide-based intercellular sig-
nalling.
This review summarizes the properties of a family of
ecto-nucleotide pyrophosphatases/phosphodiesterases (E-
NPPs) that has been identified over the last 10 years, which
hydrolyzes 5V-phosphodiester bonds in nucleotides and their
derivatives, resulting in the release of 5V-nucleotide mono-
phosphates [1, and references therein]. So far, three mem-
bers (NPP1-3), characterized by a similar modular structure,
have been cloned and intensively studied. Based on
sequence homology with the catalytic site of E-NPPs,
NPP4 and NPP5 have been identified as additional members
of the E-NPP family, but little is known concerning their
catalytic activity.
Current evidence suggests that E-NPPs have multiple and
largely related physiological roles, including nucleotide
recycling, modulation of purinergic receptor signalling,
regulation of extracellular pyrophosphate levels, stimulation
of cell motility, and possible roles in regulation of insulin
receptor (IR) signalling and activity of ecto-kinases. Aber-
rant expression of E-NPPs has been demonstrated in several
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pathologies including bone mineralization dysfunction, cell
motility and migration, angiogenesis, tumor cell invasion,
and type 2 diabetes, but the underlying mechanisms largely
remain to be determined.
Recently, the substrate range of the E-NPP family has
been broadened by showing that autotaxin (NPP2) hydro-
lyzes lysophosphatidylcholine (LPC) into lysophosphatidic
acid (LPA), which is known to activate G protein-coupled
receptors [2,3]. This exciting observation provides a con-
vincing mechanistic link between enzyme expression and
control of cell motility, and illustrates the basic principle that
the ultimate action of these enzymes in physiological and
pathological processes is the outcome of both expression
levels and local availability of substrates.
2. The E-NPP multigene family
E-NPPs belong to a multigene family that currently
contains five members. The E-NPPs have been discovered
and rediscovered independently by several different labo-
ratories, resulting in a confusing nomenclature (Table 1).
Throughout this review, we will use the current nomencla-
ture by which the E-NPPs are numbered according to their
order of discovery (NPP1-5). A phylogenetic tree shows
the relationships among the members of the E-NPP family
(Fig. 1).
2.1. Domain structure and catalytic mechanism
NPP1-3 are type II transmembrane glycoproteins char-
acterized by a similar modular structure composed of a short
amino-terminal intracellular domain, a single transmem-
brane domain, and a large extracellular domain [1]. The
latter domain contains two somatomedin B-like motifs, a
conserved catalytic site, a nuclease-like sequence, and a pu-
tative C-terminal ‘EF-hand’ motif, although the latter is
controversial and has not been directly demonstrated. NPP1
and NPP2 are disulfide-bound homodimers whereas NPP3
is monomeric. In contrast, NPP4-5 have a predicted type I
transmembrane orientation with a short intracellular car-
boxy-terminal domain, a significantly smaller extracellular
domain as compared to NPP1-3 and an unknown oligomeric
structure. The extracellular domain only contains a phos-
phodiesterase motif.
The short intracellular N-terminal (NPP1-3) and C-ter-
minal (NPP4-5) domains show a striking lack of conserva-
tion between the different isoforms. NPP1 has a longer
intracellular domain than NPP2 and NPP3. The human and
rat/mouse NPP1domains differ in length and contain 76 and
58 amino acids, respectively [4], while the NPP2 and NPP3
domains contain only 10 and 22 amino acids, respectively
[1]. Computation of the secondary structure probabilities
http://bmerc-www.bu.edu/psa) predicts the presence of four
loop-connected short helices in the N-terminal domain of
human NPP1 and one or two sequential helices in rat and
mouse NPP1 (Slegers, unpublished data). The N-terminal
sequence of NPP1 and NPP3 contains information for the
specific membrane targeting in polarized cells. NPP1 is
localized at the basolateral membrane of hepatocytes
although it is not endocytosed, whereas NPP3 is targeted
apically [5]. The basolateral signal sequence has been
identified as a di-leucine motif (AAASLLAP) localized in
the intracellular domain [6]. Mutation of this motif targets
NPP1 to the apical membrane. In addition, incorporation of
the di-leucine motif into the cytoplasmic domain of NPP3
results in its retention in the basolateral membrane. When
six residues upstream of the di-leucine motif are deleted,
NPP1 is sequestered intracellularly, indicating that sequen-
ces flanking the di-leucine motif are also important. The
Table 1
Members of the E-NPP family
Name/gene Historical names Proposed function References
Physiological Pathological
NPP1 PC-1, PC.1, MAFP,
NPPase, NPPg
Nucleotide recycling,
calcification
OPLL, CPPD disease,
type 2 diabetes
[31,35,197–199]
enpp1 (6q22–23) PDNP1, NPPS, Pca-1
NPP2 Autotaxin, PD-1a, NPPa Calcification, regulation
of cell motility
Increased tumor motility
and invasion, angiogenesis
[25,42,49,199]
enpp2 (8q2) PDNP2
NPP3 gp130RB13-6, B10, PD-Ih, NPPh Nucleotide recycling Increased tumor invasion [5,10,37,50,199]
enpp3 (6q22) PDNP3, Pdnpno
NPP4 – – – [11]
enpp4 (6p12.3)
NPP5 – – – [11]
enpp5 (6p11.2–21.1)
Nomenclature of E-NPP family members. This table provides an overview of the historical names and the proposed functions of E-NPPs in physiological
processes and pathological conditions. OPLL: ossification of the posterior longitudinal ligament of the spine; CPPD: calcium pyrophosphate dihydrate; PC-1:
plasma-cell differentiation antigen-1; MAFP: major aFGF-stimulated protein; NPP: nucleotide pyrophosphatase; PDNP: phosphodiesterase nucleotide
pyrophosphatase; PD-I: phosphodiesterase I.
Splice variants are indicated by Greek suffixes. The encoding gene is designated enpp followed by the same numerical suffix as the protein [200].
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signals responsible for apical localization and those that
distinguish endocytosis from basolateral targeting remain to
be determined [6].
The extracellular domain of NPP1-3 contains two soma-
tomedin B-like repeats proximal to the plasma membrane.
These cysteine-rich tandem repeats are similar to the soma-
tomedin B domains of vitronectin, the eight cysteine resi-
dues being in homologous positions in the sequence
suggesting a linear uncrossed pattern of disulfide bonds
[7]. These domains appear to contribute to the correct
processing and folding of NPPs, because their deletion from
NPP1 results in retention of the enzyme in the endoplasmic
reticulum (ER) (Belli and Goding, unpublished data).
NPP1-3 are classified as alkaline ecto-nucleotide pyro-
phosphatase [EC 3.6.1.9]/phosphodiesterase I [EC 3.1.4.1]
[8–10] and catalyze the hydrolysis of pyrophosphate and
phosphodiester bonds in a two-step mechanism in which
two essential divalent metal ions are required for the
formation of a nucleotidylated active-site threonine inter-
mediate and the subsequent release of nucleoside 5V-mono-
phosphate [1,11]. A putative ‘EF-hand’ Ca2 +-binding motif
(DXD/NXDGXXD) located in the C-terminal part of the
extracellular domain is essential for the catalytic activity of
NPP1 and NPP3 [1,12]. However, deletion of this motif in
NPP2 only slightly affects its enzymatic activity and has no
effect on its motility stimulating property, indicating that
binding of the required divalent ions is not mediated by this
region in NPP2 [13]. A structural model of the conserved
catalytic site and a schematic overview of the catalytic cycle
have been published by Gijsbers et al. [11], who also
commented that the putative ‘EF-hand’ motif did not satisfy
the structural criteria derived from proteins in which this
motif is functional in Ca2 + binding.
The catalytic activity of E-NPPs is inhibited ‘in vitro’ by
the glycosaminoglycans heparin, heparan sulfate, and a
variety of other substances including imidazole, 2-mercap-
toethanol, dithiothreitol, diethylpyrocarbonate, and metal
ion-chelating agents [11,14–16]. At present, no physiolog-
ical inhibitors of E-NPPs have been identified that act ‘in
vivo’.
Radioactive labeling of the active site threonine is
observed upon incubation of purified NPP1 and NPP2 with
[g-32P]- and [a-32P]-ATP [15,17–20]. The labeling repre-
sents formation of catalytic pyrophosphatase intermediates.
At low ATP concentration, autophosphorylation of the
enzyme has been observed that inhibits the enzymatic
activity and is proposed to be an autoregulatory mechanism
reversed upon addition of nucleotides to a concentration
exceeding 5 AM [15]. This autophosphorylation is a reflec-
tion of an intrinsic alkaline phosphatase activity resulting in
the formation of a covalent phospho-intermediate [11].
Claims that NPP1 has protein kinase activity are controver-
sial and have not been confirmed [18].
NPP1-5 contain 4 to 10 putative N-glycosylation sites
(Asn-X-Ser/Thr). The glycans constitute up to 15 kD of
their molecular weight [10,21], but as is the case for most N-
linked glycans, their function remains poorly understood.
They may contribute to correct transport of E-NPPs to the
plasma membrane but are not necessary for the apical
targeting of NPP3, nor are they required for the motility
stimulating property of NPP2 [22,23].
Active soluble forms of NPP1-3 have been described in
serum and conditioned medium [16,21,24–27]. NPP2 and
NPP3 are cleaved outside the transmembrane region, gen-
erating a catalytic active soluble fragment of 125 kD that
includes the somatomedin B domains and the nuclease-like
Fig. 1. Phylogenetic tree of E-NPPs. The relationship within the E-NPP family is deduced from sequence alignments. NPP1 displays a mean (human, mouse,
rat) amino acid identity of about 42% and 49% with NPP2 and NPP3, respectively, and NPP2 has a mean amino acid identity of 45% with NPP3. The mean
amino acid identity between NPP4 and NPP5 is 43% but is much lower with NPP1-3 (17–25%). A viral homologue of NPP (FP-PC1) encoded by the Fowlpox
virus has a mean 34% amino acid identity with mammalian NPP1. Although originally designated FP-PC1, it also has about 33% amino acid identity with both
NPP2 and NPP3. The amino acid identity with NPP4 and NPP5 is only about 15%. Protein sequences are retrieved from GenBank and aligned with
CLUSTALX. h: human; m: mouse; r: rat. hNPP1: AAF36094; hNPP2: BAA08260; hNPP3: AAC51813; hNPP4: BAA74902; hNPP5: CAB56566; rNPP1:
AF320054; rNPP2: BAA05910; rNPP3: BAA06333; rNPP4: XP_236955; rNPP5: XP_236956; mNPP1: AF339910; mNPP2: AF123542; mNPP3: constructed
from mouse ESTs BF123542, BF108406, AAHO5527, BE376939, AW318979; mNPP4:AAH27749; mPP5: AAH11294; Fowlpox virus: AAF44374. The bar
indicates 0.1 substitution per site.
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domain [24–26]. Human NPP1 transfected in COS 7 cells is
cleaved close to the transmembrane domain, generating an
active soluble enzyme with K113EVKS. . . as N-terminal
sequence [16]. It is not clear whether these soluble NPPs
represent alternative splice products or have been generated
by proteolytic cleavage, and their physiological signifi-
cance, if any, is currently unknown.
2.2. Tissue distribution
NPP1-3 have been detected in almost all tissues [1]
although individual isoforms are usually confined to spe-
cific substructures and/or cell types [9,28–30]. In addition,
NPP members have been localized in different cellular
compartments and are differentially targeting to plasma
membranes of polarized cells, suggesting specific physio-
logical functions of NPPs in cells and tissues.
NPP1 was originally discovered on the surface of mouse
B-lymphocytes by Takahashi et al. [31] as the plasma cell
differentiation antigen (PC-1). In mice, expression is high
on antibody-secreting plasma cells (typically less than 1% of
splenic lymphocytes), but very low or absent from immature
and mature T- and B-lymphocytes. Distribution of NPP1 in
human lymphocytes has been much less intensively studied.
Expression is low or absent from most human T- or B-
lymphocytes, although it can be up-regulated upon activa-
tion of human T-cells [32]. Little is known concerning
expression of NPP1 on human plasma cells. Human NPP1
is highly expressed in bone and cartilage cells with inter-
mediate expression in heart, liver, placenta, and testis. In
addition, NPP1 is also present on the distal convoluted
tubules of the kidney, epithelium of salivary gland ducts,
brain capillary endothelium, and the epididymis [28,33–
37]. No expression of NPP1 has been detected in neurons
and glial cells, although it has been detected in rat C6
glioma cells [38].
NPP2 was discovered as an autocrine motility factor
(autotaxin, NPP2a) in the conditioned medium of the
human melanoma cell line A2058 [24]. It is mainly
expressed in human brain, placenta, ovary and small intes-
tine, and is undetectable in lymphoid tissues [39]. In rat and
mouse, NPP2 is expressed on ciliary, choroid plexus and iris
pigment epithelial cells, cartilage and cranial bone [9,40,41].
In the rat, expression of NPP2a (p421.HB) has been
correlated with intermediate stages of oligodendrocyte dif-
ferentiation and early events in the formation of the myelin
sheet [40]. To date, two splice variants NPP2h and NPP2g
have been identified. NPP2h was identified in human
teratocarcinoma and retina, and lacks a highly basic 52-
amino-acid region located in the central domain [39,42]. Rat
brain NPP2g (PD-Ia), expressed in glial cells of the
cerebellum, differs from NPP2h by the presence of 25
additional residues in the C-terminal region of the protein
[9].
NPP3 (gp130RB13-6) was initially recognized by the
monoclonal antibody RB13-6 as a 130-kD glycoprotein
on a specific subset of rat brain glial precursor cells with
an intermediate expression of glial fibrillary acidic protein
[10,30]. Expression of NPP3 is not observed in mature
astrocytes, indicating that its expression is dependent on the
stage of differentiation. NPP3 is also a marker of activated
basophils and is identical to the activation molecule detected
by monoclonal antibody 97A6 [43,44]. Activation of baso-
phils by cross-linking IgE bound to Fcq receptors results in a
dose-dependent up-regulation of NPP3. NPP3 has also been
identified on human prostate [37], rat intestine, and the
apical hepatocyte membrane [5]. It is also expressed on
uterus, colon, basophils, mast cells and their progenitors,
and on PC12, a tumor cell line resembling sympathetic
neurons [37,43–45]. Although NPP3 is not expressed in
liver, pancreas, and small intestine in human, it is detected
in these tissues in rat [5,12,37].
The human genes enpp1 and enpp2 (encoding NPP1 and
NPP2) have been mapped to chromosome 6q22-23 and
8q24.1, respectively [35,46,47]. Human enpp3 has been
mapped in the vicinity of enpp1 on chromosome 6q22
[37]. The corresponding mouse genes of enpp1 and enpp2
were assigned to chromosome 10A2 and 15D2, respectively
[48,49]. Screening of the mouse genome database
(www.ncbi.nlm.nih.gov) with the EST-based mouse NPP3
sequence (Fig. 1) located the gene on chromosome 10A2.
Screening of the rat genome database located rat enpp1 and
enpp2 on 1p12 and 7q31. Rat enpp3 has been assigned to
chromosome 1p12 [50]. The genomic location of enpp3 in
the vicinity of enpp1 in human, mouse, and rat suggested
that they originated by duplication of an ancestor gene.
Database searches located the genes of enpp4 and enpp5,
encoding NPP4 and NPP5, at 6p12.3 and 6p21.1–p11.2 on
Table 2
Extracellular molecules that affect the expression of E-NPPs
NPP Effector Cell type References
NPP1 TGF-hz, IL-1h#, IL-4# Synoviocytes, [58]
TGF-hz, IL-1h#, IGF-I# Chondrocytes, [36,51,201]
TGF-hz Hepatocytes [199]
Glucocorticoid hormonesz Plasmacytoma [8]
1,25-dihydroxyvitamin D3z,
TGF-hz
Osteoblasts [71]
aFGFz, bFGFz, IL-1h# Osteosarcoma [52]
NPP2 IFN-g#, IL-1h#, IL-4# Synoviocytes [57,58]
RAz Epithelial cells,
neuroblastoma
[61,62]
BMP2z Mesenchymal
progenitor cells
[41]
bFGFz Endothelial and
smooth muscle cells
[143]
NPP3 Angiotensin II#, PDGF# Vascular smooth
muscle cells
[65]
TGF-h no effect Chondrocytes [76]
Compilation of data on the regulation of NPP expression in specific cell
types. An upward and a downward arrow indicate increased and decreased
NPP expression respectively.
BMP: bone morphogenic protein; FGF: fibroblast growth factor; IFN:
interferon; IGF: insulin-like growth factor; IL: interleukin; PDGF: platelet-
derived growth factor; RA: retinoic acid; TGF: transforming growth factor.
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the human, at 17B2 and 17C on the mouse, and both at 9q12
on the rat genome, respectively.
2.3. Regulation of expression
Although E-NPPs have been intensively investigated in
the past few years, little is known about the regulation of
their expression. Expression appears to be constitutive in
some cell types, e.g. plasma cells and chondrocytes, but
inducible in others. Published data compiled in Table 2
indicate that the TGF-h signalling pathway has an impor-
tant function in NPP expression (Fig. 2) and demonstrate a
growth factor-dependent but cell proliferation-independent
increase in NPP expression. TGF-h up-regulates the
expression of NPP1 in chondrocytes and osteoblasts, but
does not induce expression in osteosarcoma cells, in which
an FGF-induced expression was demonstrated [51,52]. In
chondrocytes the TGF-h induction of NPP1, accompanied
by an enhanced transport to the plasma membrane, is
antagonized by interleukin-1h (IL-1h) [36,51]. NFn-B-
mediated induction of Smad7 or inhibition of the transcrip-
tional activity of Smad3 by SAPK/JNK activated c-Jun or
JunB has been reported to underlie the inhibition of TGF-h
signalling by IL-1 (Fig. 2) [53,54]. NPP1 is expressed
constitutively at high levels by mouse plasmacytoma cells,
but its expression can be increased by glucocorticoids [8].
Whether enhanced NPP1 expression is due to sequestration
of proinflammatory transcription factors (AP-1, NFAT,
NFn-B, STATs) by the glucorticoid–glucocorticoid recep-
tor complex, and activation of TGF-h signalling upon
attenuation of inhibitory Smad expression (Fig. 2), remains
to be determined.
The expression of NPP2 and NPP3 increases during
osteogenic and chondrogenic differentiation induced by
bone morphogenic protein-2 [41,55]. In fibroblast-like syn-
oviocytes of patients with rheumatoid arthritis that express
high levels of TGF-h [56], NPP2 expression is strongly
increased and is down-regulated by interferon-g (IFN-g )
and IL-1h [57,58]. These cytokines may down-regulate
NPP2 expression by induction of the TGF-h signalling
inhibitors Smad6 and Smad7 (Fig. 2) [53,59]. Retinoic acid,
an inducer of TFG-h in neuroblastoma cell lines, increases
the expression of NPP2 and potentiates the Wnt-1 mediated
expression of NPP2 in C57MG mouse mammary epithelial
cells [60–62]. Furthermore, TGF-h activates the SAPK/
JNK pathway via MKK4/MKK7 in a Smad-independent
manner [63] and MKK7 has been shown to up-regulate the
expression of NPP2 in human embryonic kidney cells [64].
Fig. 2. Pathways that modulate the signal transduction of TGF-h affect NPP expression. TGF-h/activin and BMP receptor activation phosphorylates the C-
terminal -SSXS- sequence ( ) of R-Smad 2, 3 and 1, 5, 8 respectively. Complete activation and nuclear translocation of phosphorylated Smads requires the Co-
Smad 4 or co-activator CBP/p300. The activated complex binds to the Smad-binding element (SBE, -AGAC-) of TGF-h responsive genes. Putative SBEs are
present in the promoter of hNPP1 (AB032016) at positions  188,  242,  358,  464 and  671; of hNPP2 (D45914) at positions  79,  531,  1485
and  1745; and of hNPP3 (AF119714) at positions  60 and  65. The nucleotide before the ATG start codon is taken as  1. IFN-g and IL-1h antagonize
TGF-h signalling by a cell-specific induction of the inhibitory Smad 7 (I-Smad) mediated by activation of STAT and NF-nB, respectively. Glucocorticoid
(GC)–glucocorticoid receptor (GR) complexes sequester NFnB that becomes inactive in gene transcription. I-Smad associates with the TGF-h type I receptor
and prevents the association of R-Smads. TGF-h receptors also activate JNK by a Smad-independent feedback mechanism involving activation of the MAPK/
ERK kinase kinase (MEKK) 4/7. MEKK 4/7 is also activated by the IL-1 receptor-associated kinase (IRAK). Depending on the cell type, JNK activates cJun/
JunB that associates with Smad 3 into an inactive complex (red arrow) or JNK phosphorylates Smad 3 outside its -SSXS- motif [P], resulting in an enhanced
activation and nuclear accumulation. TFG-h and angiotensin II (ANG) receptors transactivate the EGF receptor by a metalloprotease-dependent mechanism
resulting in MAPK/ERK activation. Phosphorylation of Smad 1, 2 and 3 by MAPK outsite its -SSXS- motif ([P]) inhibits its translocation to the nucleus.
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Angiotensin-II and platelet-derived growth factor
(PDGF) decrease NPP3 expression in vascular smooth
muscle cells (VSMC) [65]. Angiotensin, an inducer of
PDGF-B expression in newborn rat VSMC, negatively
regulates TGF-h/Smad signalling by a Ras/ERK-dependent
mechanism involving transactivation of the EGF-receptor
(Fig. 2) [66,67].
3. Physiological and pathophysiological functions of E-
NPPS
E-NPPs hydrolyze a broad range of substrates and
influence many physiological processes. Dysfunction of E-
NPPs has been shown to be involved in the pathophysiology
of several diseases, although it is often unclear whether
changes in E-NPP expression are a cause or an effect of the
disease.
3.1. E-NPP regulates bone and cartilage mineralization
3.1.1. NPP1 controls mineralization
A tight balance between pyrophosphate (PPi) and ortho-
phosphate (Pi) concentration governs physiological miner-
alization processes in bone, teeth, and growth plate cartilage
[68,69]. PPi is required to induce calcification [70], the main
extracellular source being hydrolytic degradation of nucleo-
side triphosphates by NPPs (Fig. 3). NPP1 has been
correlated with matrix vesicle (MV) nucleotide pyrophos-
phatase activity and the generation of intravesicular and
extracellular PPi (ePPi), and has been identified as the main
ePPi-generating enzyme of osteoblasts and chondrocytes
[29,36,71]. Matrix calcification by osteoblasts is mediated
by release of PPi-enriched MVs. These vesicles contain
proteins that sequester calcium and a cascade of hydrolytic
enzymes including alkaline phosphatase, ATPase, and
NPP1. These enzymes control the release of Pi and PPi
from ATP as well as the conversion of PPi into Pi [72]. In
extracellular fluids calcium and phosphate concentrations
are close to the deposition point of basic calcium phosphate
(BCP, hydroxyapatite).
PPi not only initiates but also regulates mineralization by
suppressing hydroxyapatite crystal deposition from amor-
phous calcium phosphate, pointing to NPP1 as an important
regulator of mineralization [73–75]. In addition, elevated
levels of ePPi often result in pathological calcification
characterized by the formation of calcium pyrophosphate
dihydrate (CPPD) crystals. A distorted balance of Pi/PPi
still allows crystal nucleation but ultimately leads to abnor-
mal ossification, since PPi also functions as a physiological
inhibitor of this process (Fig. 3).
Growth factors and interleukins that regulate the
expression of NPP1 (Table 2, Fig. 2, and Section 2.3)
determine the rate and extent of mineralization. A modest
increase in NPP1 is sufficient to significantly increase
ePPi [76].
Fig. 3. Pyrophosphate in physiological and pathophysiological calcification processes. Intracellular pyrophosphate (iPPi) is generated in matrix vesicles (MV)
by hydrolysis of NTP by NPP1 and in the lumen of the endoplasmic reticulum (ER) mainly by NPP3. Mitochondria have been reported to contribute to and
regulate iPPi (for a review see Ref. [69]). ANK transports iPPi outside the cell. Extracellular PPi (ePPi) is mainly generated by membrane-bound and soluble
NPP (sNPP) 1–2. In physiological conditions ePPi is hydrolyzed by alkaline phosphatase (AP) into Pi that, together with Ca2 +, is integrated into basic calcium
phosphate (BCP, hydroxyapatite) crystals. BCP crystal formation is controlled by ePPi. Excess ePPi results in pathological calcification characterized by
calcium pyrophosphate dihydrate (CPPD) crystal formation. A low level of ePPi causes pathological calcification of ligaments and joints.
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In chondrocytes, NPP1 generates PPi in both the ER and
Golgi during its transport to the plasma membrane. In
contrast, NPP3 (B10), which is predominantly localized in
the ER, mainly contributes to intracellular PPi (iPPi) (Fig. 3)
[76–78]. Intracellular PPi is transported out of the cell by a
probenecid-sensitive anion transport channel containing the
transmembrane protein ANK [69]. Together with PPi gen-
erated by E-NPP, ANK determines the concentration of ePPi
(Fig. 3; Section 3.1.4). Although NPP3 is present in articular
cartilage, it is unable to compensate a loss of NPP1 activity,
partly due to a different subcellular localization of NPP1 and
NPP3 [76].
3.1.2. Up-regulation of NPP1 is associated with chondro-
calcinosis
Since the pyrophosphate (PPi) and inorganic phosphate
(Pi) concentration is critical for physiological mineraliza-
tion, regulation of NPP1 expression must be tightly con-
trolled. There is considerable body of experimental evidence
that increased NPP1 levels may contribute to the develop-
ment of pathological mineralization (reviewed in [79]).
TGF-h, present in a latent form in cartilage, potently
increases PPi generation as a result of an increased expres-
sion of NPP1 on chondrocytes [51,80,81].
There is increasing evidence that PPi levels are regulated
by opposing actions of NPP1, which generates PPi, and
tissue-nonspecific alkaline phosphatase (TNAP), which
degrades PPi into Pi [82]. Consistent with this idea, PPi
levels are increased by TGF-h-induced up-regulation of
NPP1 and down-regulation of alkaline phosphatase [51].
The TGF-h-mediated up-regulation, as well as the basal
NPP1 level, is antagonized by the proinflammatory cytokine
IL-1h [51]. The observed increase in IL-1h levels in
patients with rheumatoid arthritis, as compared to patients
with osteoarthritis and normal individuals, down-regulates
NPP1 and may account for the decreased synovial PPi levels
and the decreased bone calcification density in this disease
[81,83,84].
Pathological mineralization is often accompanied by
crystal deposition in joints due to increased PPi formation.
In idiopathic chondrocalcinosis or CPPD deposition disease,
an elevated PPi concentration in joints can be partially
accounted for by an increased NPP1 activity [85–88].
Crystal formation is further facilitated by the fact that the
synovial fluid of these patients has an ATP concentration
(200 nM) that is twice that in normal joints [89]. Deposition
of BCP crystals is frequently observed in this condition
[88], but whereas BCP crystal deposition is correlated with
joint degeneration, often in association with acute arthritis,
CPPD crystal formation appears in an age-dependent man-
ner [81].
3.1.3. Deficiency of NPP1 is associated with pathological
calcification of ligaments and joint capsules
Since NPP1 is a major source of ePPi, and PPi is a potent
inhibitor of hydroxyapatite formation, it seemed reasonable
to expect that deficiency of NPP1 might result in patho-
logical calcification. This has been shown to be the case in
ttw (tiptoe walking) mice where the NPP1 gene is disrupted
by a natural recessive mutation [90]. An essentially identical
phenotype is seen in mice in which the NPP1 gene is
disrupted by homologous recombination [91]. In each case,
the mice show an increasing age-dependent calcification of
ligaments, joint capsules, and tendons.
In view of the opposing and reciprocal actions of NPP1
and TNAP in the production and hydrolysis of ePPi, it is
interesting to note that ‘double knockout’ mice in which
both genes were deleted have a less severe phenotype than
single knockouts where only the TNAP gene was deleted
[82,92].
The only reported case of NPP1 deficiency in humans
was in a 2-year-old boy with iodopathic infantile arterial
calcification, in which there was peri-arterial and peri-
articular calcification [93]. This child had very low NPP1
levels, and was heterozygous at the enpp1 locus, although
the coding sequence was normal. The exact nature of the
defect was not established.
A much more common human condition in which
abnormalities of NPP1 expression have been suspected is
ossification of the posterior longitudinal ligament of the
spine (OPLL), which is a significant cause of myelopathy
especially in Japan and Southeast Asia. The disease
involves ectopic bone formation in the paraventral ligament
and spinal-cord compression [94]. Genetic analysis of the
NPP1 gene in OPLL reveals a significant association with a
mutation in intron 20 [95]. Deletion of T, 11 nucleotides
upstream from the splice acceptor site of intron 20, appears
to render individuals more susceptible to abnormal ossifi-
cation of the spinal ligaments [95].
There are a number of similarities between the ttw mice
and human OPLL [90,96,97]. However, it cannot be
assumed that the ttw mouse is an exact homologue of
human OPLL. Unlike OPLL, the observed heterotypic
ossification in ttw mice does not only occur in the spinal
ligaments, but also in the joint capsules, tendons, tendon
entheses, cartilage, and peripheral ligaments [90]. However,
no convincing evidence for a changed NPP1 activity in
OPLL has yet been reported, and the association with the
variant sequence in intron 20 has not been shown to result in
changed NPP1 activity.
3.1.4. Extracellular PPi is determined by NPP1 and ANK
From the foregoing, it would appear that the concen-
tration of ePPi must be maintained within a very narrow
range. Too little pyrophosphate causes the pathological
deposition of hydroxyapatite, while too much causes the
deposition of CPPD crystals (Fig. 3).
This point is reinforced by a second mutant strain of mice
(ankylosing, or ank), in which a completely different gene is
involved, but the phenotype is remarkably similar to that of
ttw and NPP1-knockout mice. In each case, the mutations
are associated with decreased ePPi. The mutation in ank
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mice resides in a gene that encodes a multipass transmem-
brane protein that appears to be a pyrophosphate transporter
[98]. The mutation has been shown to involve loss of
function, with increased iPPi and reduced pyrophosphate
export, consistent with its recessive inheritance [98]. These
results are consistent with the NPP1 mutants, in that reduced
levels of ePPi promote the excessive deposition of hydrox-
yapatite.
These data are extended by recent studies of mutations in
the human ank gene. Remarkably, mutations have been
found involving loss and gain of function. Both result in
pathological calcification, with deposition of hydroxyapatite
and CPPD, respectively [99]. A French family was found to
have a recessive mutation in the first transmembrane region
that resulted in loss of function, elevated iPPi, and presum-
ably reduced ePPi. Loss of ank function was accompanied
by deposition of hydroxyapatite in and around joints, similar
to the ank mouse.
In contrast, a British family was found to have a
dominantly inherited mutation in the ank gene, resulting
in addition of four amino acids at the N terminus. This
mutation was accompanied by a gain of function, with a
modest increase in the ability to export pyrophosphate.
Several other ‘‘gain of function’’ mutants were also found.
In each case, the ‘‘gain of function’’ mutants were accom-
panied by the deposition of CPPD characteristic of the
common sporadic forms of human chondrocalcinosis [99].
These results seem consistent with the evidence that
increased pyrophosphate generated as a result of NPP1
activity may play a causal role in the common forms of
chondrocalcinosis [100].
The functional relationships, if any, between the ANK
protein and NPP1 remain to be discovered. Loss of one
allele of one gene is not sufficient to cause disease, but the
loss of two alleles at either locus causes pathological
deposition of hydroxyapatite. It would be interesting to
examine the phenotype of mice that are heterozygous for
both loci.
The striking similarities between under- and over-activ-
ity of NPP1 and ANK proteins suggest a functional
relationship. Do they work sequentially or independently?
Sequential action may explain some of the data but has
several difficulties. Pyrophosphate would be generated by
NPP1 in the interior of intracellular organelles, transported
into the cytosol, and then transported out of the cytosol to
the exterior of the cell via ANK (Fig. 3). Homozygous
disruption of either gene would result in pathological
deposition of hydroxyapatite. Although NPP1 must be
present in the ER and Golgi on its way to the cell surface,
the pH inside these organelles is mildly acidic and since the
pH optimum for NPPs is rather alkaline, this would result in
very low enzyme activity. At the present time, it seems
more likely that these pathways are independent and
operate in parallel, with an independent source of cytosolic
PPi, perhaps from exchange with ADP in mitochondria
[69].
To summarize, it must be concluded that the ank and ttw
mice confirm the importance of maintenance of a narrow
range of ePPi to prevent pathological calcification, but the
details of the way that these pathways interact with each
other have yet to be elucidated.
3.2. E-NPPS modulate nucleotide-mediated signal trans-
duction
3.2.1. Modulation of purinergic receptor signalling
Extracellular nucleotides, and in particular ATP and
adenosine, elicit a broad range of responses in biological
processes as diverse as neurotransmission, neuroprotection
in hypoxia and ischemia, regulation of cardiovascular func-
tion, platelet aggregation, smooth muscle contraction, secre-
tion of hormones, modulation of the immune response and
control of cell proliferation, differentiation and apoptosis
(Fig. 4) [30,45,101–110].
In neurons, ATP is stored in synaptic vesicles in milli-
molar concentrations and is released into the synaptic cleft
upon excitation. There is also a large and convincing body
of evidence that ATP and UTP can be specifically released
from non-neuronal cells by non-lytic transport-mediated
mechanisms [111–114]. Both pre- and post-synaptic neuro-
modulation by ATP and its degradation product adenosine
have been demonstrated, and are mediated by the activation
of P2 and P1 purinergic receptors, respectively [115,116].
NPPs and other ecto-nucleotidases differentially expressed
on specific cell types can hydrolyze ATP and generate
adenosine, and thereby have the potential to terminate
signalling by P2 receptors and activate signalling by P1
(Fig. 4).
Nucleotides have been shown to affect the proliferation
of different cell types, although the results are not always
unequivocal and the mechanisms may be complex and
indirect, depending on the cell type and the presence of
ecto-nucleotidases. ATP stimulates the proliferation of pri-
mary astrocytes and aortic smooth muscle cells but has no
effect on the growth of transformed mouse fibroblasts [117–
119]. In contrast, several tumor cell lines are growth-
inhibited in response to ATP [120,121]. Adenosine inhibits
or stimulates the proliferation of cells depending on its
extracellular concentration and on the cell type [108,122,
123].
The different effects of ATP and adenosine may be
understood as reflecting the final outcome of differential
expression of purinergic receptor subtypes, together with
the modulating effects of cell surface-bound nucleotidases
which have the potential to generate active signalling
ligands or terminate signalling by hydrolyzing them at
the surface of specific cells [30,45,107,108,124]. These
enzymes include members of the ecto ATPase, ecto-
apyrase, E-NPPs and ecto-nucleotidase families which
hydrolyze ATP into ADP, AMP, and adenosine [124],
resulting in the stimulation of distinct nucleotide receptor
subtypes which are linked to the activation of ligand-
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gated cation channels, phospholipase C, or adenylate
cyclase.
For example, modulation by NPP1 of the activation of
the P2Y12 receptor, negatively coupled to adenylate cyclase,
has been demonstrated in rat C6 glioma cells [38,125,126].
Modulation of the action of ATP on these cells by NPP1
seems to involve several different mechanisms. Both ATP
and adenosine inhibit the growth of C6 cells. However, if
the enzymatic activity of NPP1 is inhibited, ATP becomes a
growth stimulator of these cells, suggesting that hydrolysis
of ATP into AMP and subsequently into adenosine by 5V-
nucleotidase is responsible for the observed ATP-mediated
growth inhibition [121]. Inhibition of cell growth by ATP
might be an indirect effect explained by cellular uptake of
adenosine by specific transporters and induction of pyrimi-
dine starvation [127,128]. The data might also be explained
on the basis that inhibition of hydrolysis of extracellular
ATP by blocking NPP1 would shift the balance towards P2
receptor activation and prevent P1 receptor activation. A
third possible mechanism could involve the modulation of
the activity of growth factors and growth inhibitors by
extracellular kinases which are directly coupled to the level
of the g-phosphate donors and may also affect cell growth
[129, and references therein].
E-NPPs have also been proposed to play a role in ATP-
induced apoptosis [130]. ATP-mediated apoptosis may
result from either activation of the P2X7 receptor as shown
for mast cells, platelets, macrophages, and lymphocytes
[109], or generation of adenosine and activation of the A3
(P1 purinergic) receptor as shown for astrocytes, neuro-
blastoma, and mesangial cells [110,131]. Pyridoxalphos-
phate-6-azophenyl-2V, 4V-disulfonic acid, a potent inhibitor
of NPP1 [125], has been shown to abolish ATP-induced
apoptosis in the mouse neuroblastoma cell line N1E-115 by
inhibition of the hydrolysis of ATP into adenosine [110].
The neuroprotective effect of adenosine in hypoxia/ischemia
may also be due to inhibition of neurotransmitter release by
activated A1-receptors [104,132]. In this case, as previously,
adenosine could be derived from ATP by the action of ecto-
nucleotidases.
3.2.2. Nucleotide recycling
Proliferating cells have a large requirement for purine
and pyrimidine nucleotides, which may be generated de
Fig. 4. Effect of NPP on purinergic and lysophosphatidic acid (LPA) receptor signalling. Depending on the cell type, purinergic and LPA receptors can activate
Gi-, Gs-, Gq- and G12/13-coupled (blue boxes) signal transduction pathways. NPPs hydrolyze nucleotide di- and triphosphates into monophosphates and
terminate P2X and P2Y receptor signalling coupled to Ca2 +-influx and to Gi (P2Y12, 13), Gs (P2Y11) and Gq (P2Y1, 2, 4, 6, 11) proteins. P2Y receptors are
coupled to RhoA and can activate MAPK by a RhoA- and novel PKC (nPKC)-dependent or a PLC- and conventional PKC (cPKC)-dependent pathway, and
modulate AC by Gi and Gs proteins. AMP is hydrolyzed into adenosine (Ado) by 5V-nucleotidase (5V-Nu). Ado activates P1 receptors that modulate AC by Gi
(A1, A3) and Gs (A2) proteins, and activate PLC (A1, A3) by Gq/11. Ado is internalized by nucleoside transporters. NPP2 hydrolyzes lysophosphatidylcholine
(LPC) into LPA resulting in stimulation of LPA receptors. These receptors can couple to Gi/o (Gi), G12/13 and Gq proteins resulting in the activation of several
signalling pathways including Gi protein-mediated inhibition of adenylate cyclase (AC), Gq protein-mediated activation of MAPK involving phospholipase C
(PLC) and conventional PKC (cPKC), G12/13 protein-mediated activation of PI 3-Kg (p110g) and its downstream effectors RhoA and phosphatidylinositol-
dependent kinase (PDK)-1, or activate MAPK and PI 3-Kh (p110h) by transactivation of the epidermal growth factor (EGF) receptor. The small GTPase RhoA
is coupled to Rho-associated coiled-coil-containing protein kinase (ROCK) involved in the reorganization of the cytoskeleton. Downstream effectors of PI 3-K
and PDK-1 are PKB and PKC~ . PKB regulates the cell cycle by phosphorylation of glycogen synthase kinase-3 (GSK-3). PKC~ is involved in invasion by
activation of NFnB, a transcription factor of matrix metalloprotease (MMP) genes.
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novo or recycled from extracellular nucleotides through a
salvage pathway. E-NPPs are proposed to be part of a
hydrolytic cascade system that culminates in the conversion
by 5V-nucleotidase of nucleoside monophosphates into
nucleosides that are then internalized by cells through
specific nucleoside transporters [133]. A function for E-
NPPs in this salvage pathway has been demonstrated in
T-lymphocytes, hepatocytes, and the intestine when de
novo synthesis is inhibited by azaserine [32]. T-lymphocyte
proliferation is dependent on the presence of extracellular
NAD+, ADP-ribose, or AMP. Degradation of extracellular
NAD+ proceeds through the concerted action of CD38,
which is an ecto-NAD+-glycohydrolase, and NPP1 [32].
CD38 generates ADP-ribose, which is subsequently hydro-
lyzed into AMP by NPP1. Ecto-5V-nucleotidase finally
degrades AMP into adenosine, which is taken up by cells.
Treatment of T-lymphocytes with membrane-permeable
activators of PKA or PKC results in a coordinated up-
regulation of CD38 and NPP1 expression, suggesting a
functional hydrolysis cascade on activated T-lymphocytes
[32].
The liver secretes nucleotides into the bile as autocrine
and paracrine regulators of bile secretion [133–135]. NPP3,
expressed on the apical surface of hepatocytes, is proposed
to function in the recycling of nucleotides from bile in
rodents [5,26,133]. This mechanism would appear unlikely
in humans, since NPP3 is not expressed in human liver
[12,37] In addition, it has been suggested that NPP3 plays a
role in the intestinal uptake of nutritional nucleotides by
enterocytes [5,136].
3.3. Motility and invasion of tumor cells
NPP2 was originally identified in the conditioned me-
dium of the A2058 melanoma cell line as a factor that
promoted cell motility and given the name ‘autotaxin’ [24].
It has subsequently been detected in many tumors including
hepatocellular carcinoma [137], neuroblastoma [138], pros-
tate carcinoma [139], and non-small-cell lung cancer [140].
NPP2 has been shown to augment the invasive and meta-
static potential of ras-transformed NIH3T3 cells. Further-
more, it stimulates blood vessel formation in tumors arising
from these cells as well as in human endothelial cells,
indicating that NPP2 has angiogenic properties [142,143].
In this context, it is interesting to note that IL-4, a cytokine
reported to inhibit angiogenesis [144–146], down-regulates
NPP2 expression [58].
NPP2 stimulates both random and directed tumor cell
migration at picomolar concentrations [24], which would
only seem possible for a molecule with enzymatic proper-
ties. An important role has been attributed to the catalytic
site of NPP2 since mutation of Thr210 into Ala or Asp
abolished its ability to stimulate cell motility. It has been
proposed that dephosphorylated NPP2 actively promotes
this motility [141]. Until recently, however, it was impos-
sible to make a functional linkage between the NPP2
activity and stimulation of cell motility because there was
little evidence that this effect was mediated by nucleotides.
An exciting breakthrough in the elucidation of the NPP2
promoted motility came from the discovery that NPP2 has
intrinsic lysophospholipase D (PLD) activity that results in
the generation of LPA from plasma lysophosphatidylcholine
[2,3]. LPA is known to stimulate cell motility and invasion
by signalling pathways that activate Rho GTPases (Fig. 5)
[147].
The physiological activities of LPA are mediated by three
receptors of the endothelial differentiation gene family, e.g.
Edg2 (LPA1), Edg4 (LPA2) and Edg7 (LPA3), that can
activate Gq, Gi, and G12/13 subfamilies of G proteins. Gi is
pertussis toxin-sensitive and is coupled to Ras and MAPK
by Ghg transactivation of the p110h PI 3-K subunit recruited
to the EGF receptor (Fig. 4) [148]. This transactivation is
also required for the initiation of protein synthesis stimu-
lated by LPA-activated receptors [67]. In human melanoma
cells NPP2 has been shown to promote motility by a G
protein-coupled mechanism involving activation of the
catalytic p110g subunit of class IB PI 3-K [149]. The
discovery of lysophospholipase activity of NPP2 now
allows this observation to be integrated into the known
signalling pathway by which phosphatidic acid acts.
This activity of NPP2 was all the more surprising
because of the lack of structural similarity between this
substrate and nucleotides (Fig. 5), which had been consid-
ered the most likely physiological substrates ‘in vivo’. In
view of the high degree of conservation of the amino
sequences surrounding the active site threonine of NPPs,
the question arises whether other members of the NPP
family also have PLD activity. This issue is currently being
intensively studied.
There is some indirect evidence that this may be the case
for NPP3, which has been shown to have invasion-promot-
ing properties. In prenatal and neonatal rats, NPP3 is
expressed on a specific subset of glial cells which are highly
susceptible to malignant transformation by N,NV-ethylnitro-
sourea [10,30]. A role of NPP3 in development and tumoral
transformation was demonstrated by showing that its
expression in fibroblasts and glioma cells induced morpho-
logical changes, synthesis of differentiation specific pro-
teins, and enhanced invasive properties [150]. NPP1 is the
only E-NPP present on invasive rat C6 glioma cells
[38,107,150] but its effect on motility and invasion remains
to be determined.
NPP3 has also been suggested to be an early marker of
cholangiocarcinoma, an adenocarcinoma derived from bili-
ary cells. Its serum level increases significantly at the onset
of the disease. The slightly smaller (125 kD) soluble serum
form of NPP3 has been proposed to be generated by
proteolytic cleavage from the transmembrane form, but the
exact mechanism remains to be elucidated [26]. NPP3 is
expressed on the apical membrane of normal biliary cells in
rodents, and proteolytic cleavage results in secretion into the
bile [5]. However, a redistribution of NPP3 from the apical
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to the basolateral membrane in pathological conditions
allows hydrolyzed NPP3 to be secreted into the blood
stream [151,152].
NPP3 is initially transported towards the basolateral
surface. Subsequently, it is rapidly redirected towards the
apical membrane by transcytosis [153]. Alterations in trans-
cytosis in pathological conditions may lead to an abnormal
basolateral sequestering of NPP3, but the precise mecha-
nism of such redistribution is currently unclear. Although
glycosylation has an important function in the correct trans-
port of proteins to the cell surface, the glycans of NPP3 do
not appear to contain an apical targeting signal [22], and
glycosylation is not essential for transport of NPP3 to the
cell surface or for secretion.
3.4. Overexpression of NPP1 in diabetes mellitus: a
controversial issue
Non-insulin-dependent diabetes mellitus (NIDDM) is a
very common and increasingly prevalent syndrome charac-
terized by resistance to both endogenous and exogenous
insulin. In NIDDM mutations in the IR gene are extremely
uncommon [154,155], and the common forms of insulin
resistance are due to a poorly understood post-receptor
defect in the insulin-mediated signal transduction
[156,157]. Insulin resistance may precede the onset of overt
clinical disease by many years, and is correlated with an
impaired IR kinase activity, although the IR gene is com-
pletely normal [156,158,159]. The presence of an inhibitor
of IR tyrosine kinase activity in skin fibroblasts of patients
with insulin resistance was suggested by Maddux et al.
[160]. They purified a candidate inhibitor from dermal
fibroblasts derived from a NIDDM patient, and the inhibitor
was identified by partial amino acid sequencing as NPP1
[161]. The NPP1 protein level and enzymatic activity were
increased in NIDDM patients.
These results have been somewhat controversial and
there are a considerable number of studies in which no
evidence is found for a role of E-NPP in diabetes. It is not
clear whether the differing results reflect heterogeneity in
patient subgroups or possibly methodological and technical
issues. A subgroup of patients with pseudo-acromegalic
insulin resistance showed no correlation between NPP1
overexpression and defective insulin action [162]. In vitro
studies showed that overexpression of NPP1 in MCF-7 cells
rendered them less sensitive to insulin, and overexpression
in MDA-MB231 breast cancer cells was also associated
with inhibition of IR tyrosine kinase activity [163].
Although elevated plasma levels of TGF-h1 detected in
NIDDM patients [164] may be responsible for the increased
expression of NPP1, the regulation of NPP1 expression and
its correlation with insulin resistance in different diabetic
subgroups remains to be determined.
Many studies have shown a correlation between
increased NPP1 expression and insulin resistance, but most
have not addressed the question of causality. Insulin resist-
ance is observed in up to 25% of the healthy non-diabetic
non-obese individuals, and this population is at risk of
Fig. 5. Activation of lysophosphatidate (LPA) receptors by autotaxin (NPP2). NPP2 hydrolyzes lysophosphatidylcholine (LPC) into LPA and choline.
Stimulation of LPA receptors (LPA-R) activates small GTPases of the RhoA family (Cdc42, Rac, Rho) by PI 3-K-dependent mechanisms (see Fig. 4). These
GTPases are able to interact with and activate different downstream effectors [202] involved in motility-related processes, e.g. formation of membrane ruffles/
lamellipodia, filopodia, actin stress fibers and focal adhesion.
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developing diabetes if insulin resistance increases and/or
insulin secretion declines [165]. In these individuals, an
increased NPP1 protein content in adipose tissue and
skeletal muscle has been correlated with a reduction in
insulin sensitivity and IR tyrosine kinase activity [166–
168]. The NPP1 content was found to be inversely corre-
lated with the insulin-stimulated glucose transport in skel-
etal muscle [169]. An inverse correlation between NPP1
levels and IR tyrosine phosphorylation has also been
observed in muscle biopsies of obese insulin resistant rhesus
monkeys [170]. Furthermore, an increased NPP1 content
has been measured in rectus abdominus muscle biopsies and
adipocytes of pregnant females developing gestational dia-
betes mellitus (GDM) and has been proposed to contribute
to this disease, indicating a higher risk for type 2 diabetes
with age [171,172].
Clinical treatment of type 2 diabetes with the antihyper-
glycemic drugs pentoxifylline and metformin restores insu-
lin sensitivity and decreases NPP1 expression [58,173].
Merck L7, a direct IR agonist, and Teliks TLK6998, an
IR sensitizer, which belong to a new class of anti-diabetic
agents, improve IR autophosphorylation in cells overex-
pressing NPP1 [174].
An alternative approach to establish a possible causal
link between NPP1 and insulin resistance comes from
human genotyping studies. A K121Q polymorphism has
been identified in exon 4. Individuals with the Q allele
showed higher glucose levels and increased insulin resist-
ance [175]. However, this polymorphism is detected in
Sicilian, Finish, and Swedish Caucasians but is absent in
Danish Caucasians [175–177], so even if this association is
causal, additional unidentified genes must contribute to the
clinical phenotype.
The Q-allele of this polymorphism has also been linked
to a faster progression of albuminuria and nephropathy in
Italian type 1 diabetes patients [178] but was not correlated
with microvascular complications in Danish type 1 diabetics
[179]. In contrast, a study with 295 patients was unable to
correlate the K121Q amino acid variant with the progression
of diabetic nephropathy [180], while a study with 659
patients concluded that carriers of the Q variant of NPP1
have an increased risk of developing end-stage renal disease
early in the course of type 1 diabetes [181]. So far, no data
are available concerning whether the K121Q polymorphism
alters NPP1 enzymic activity.
A cluster of three single nucleotide polymorphisms
(G2897A, G2906C, and C2948T) in the 3V-untranslated
region of the enpp1 gene has been shown to increase NPP1
mRNA stability and has been correlated with an increased
NPP1 protein content and with insulin resistance [182]. In a
multipoint linkage study, enpp1 was also identified as a
positional candidate gene for insulin resistance near the
chromosomal marker D6S403 [183].
What possible mechanisms could be involved in NPP-1-
mediated insulin resistance? Early cell-free studies showing
inhibition of IR phosphorylation by NPP1 have been shown
to be artifacts due to hydrolysis of ATP by NPP1 [184]. In
vivo studies do not have this problem [185,186]. Evidence
has also been presented that the mechanism is independent
of the enzymatic activity of NPP1; inhibition of IR auto-
phosphorylation by NPP1 has been demonstrated to occur
even if NPP1 is inactivated by site-directed mutagenesis
[187]. Although adenosine produced from ATP or ADP
after successive hydrolysis by NPP1 and 5V-nucleotidase
can modulate insulin signalling through the activation of P1-
receptors [188,189], pharmacological data suggests no role
for adenosine in the pathogenesis of NIDDM [187].
More recently, immunoprecipitation experiments have
suggested that NPP1-mediated inhibition of IR function is
due to high affinity binding of NPP1 to the IR, as evidenced
by the ability of the complex to withstand repeated washing.
The observed inhibition was independent of NPP1 activity
[190]. No physical association of NPP1 with the closely
related IGF-I receptor was detected, suggesting that the
interaction between NPP1 and the IR is highly specific.
Therefore, it is surprising that NPP1 is not routinely
encountered upon purification of the IR.
Correlation of the K121Q polymorphism with a higher
risk for insulin resistance has been explained by a stronger
interaction of NPP1 with IR in individuals with the Q allele
[191]. This mutation is located in the first somatomedin B-
like extracellular domain of NPP1, suggesting an extracel-
lular interaction with IR. Deletion of the connecting domain/
fibronectin-like III domain (amino acids 485–599) of the IR
a extracellular subunit abolished its association with NPP1,
indicating that this domain is involved in the interaction
[190,192].
It should be emphasized that the reports on the involve-
ment of NPP1 in insulin resistance are not universally
accepted, and there is evidence to the contrary. Whitehead
et al. [162] demonstrated that patients with genetic lesions in
IR or insulin receptor substrate (IRS)-1 have a significant
reduction in NPP1 expression rather than the increase seen
in studies by other authors. Induction of diabetes in rats by
high fat feeding did not alter NPP1 expression, and over-
expression of the N-terminal 257 amino acid residues of rat
NPP1 did not change IR autophosphorylation, PI 3-K
activation, or glucose uptake in highly insulin-sensitive
3T3-L1 adipocytes [193]. In Fisher rats relatively resistant
to obesity, insulin resistance in muscle tissue is not asso-
ciated with a change in NPP1 level [186]. Another study
showed that overexpression of NPP1 in CHO cells did not
impair IR autophosphorylation, downstream signalling to
MAP kinase through Ras or IRS-dependent PI 3-K activa-
tion, but blocked the insulin-dependent activation of p70 S6
kinase [194].
IRS proteins have been shown to be involved in the ‘in
vivo’ insulin effects on carbohydrate and lipid metabolism
[195]. IRS-1 has a role in muscle and adipose tissue, while
IRS-2 has a major effect in liver and muscle. Defects in IR
signalling via IRS-2, involved in peripheral insulin actions
and in pancreatic h-cell functioning, contribute to insulin
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resistance. Mice lacking the irs-2 gene develop progressive
diabetes [196]. Hepatic insulin resistance is involved in this
process, and failure of a h-cell compensation results in
diabetes. It would be of interest to examine NPP1 expres-
sion in mice lacking the irs-2 gene.
In summary, evidence for a role of NPP1 in insulin
resistance is inconsistent and contradictory, for reasons that
are currently unclear. In view of the medical importance of
type II diabetes, there is an urgent need for further studies
that are capable of providing definitive answers.
4. Conclusions
Extracellular nucleotide hydrolysis has long been con-
sidered to serve a role in cellular nutrition by the removal
and recycling of nucleotides from the extracellular medium.
Recent work reveals a far more complex picture. During the
past decade it has become clear that nucleotides are medi-
ators of intercellular signalling. They control multiple phys-
iological processes initiated by activation of specific cell
surface receptors and their intracellular signal transduction
pathways. Ectonucleotidases initiate, terminate, or modulate
these signalling cascades.
It is now clear that specific ecto-nucleotidases expressed
by cells stringently regulate the ecto-nucleotide metabolism
in their microenvironment. Although E-NPPs mainly seem
to be functional in physiological processes that require a
balanced nucleotide hydrolysis, competition among the
different substrates for binding in their catalytic site may
be an additional factor that controls the processes affected
by E-NPPs.
Depending on the cell type, E-NPPs initiate the
hydrolysis of nucleotide tri- and diphosphates affecting a
broad array of processes including bone and cartilage
mineralization, recycling of nucleotides, cell motility,
and diverse purinergic receptor-dependent mechanisms.
The ability of E-NPPs to generate PPi has been shown
to have profound effects on the calcification of cartilage,
bone, ligaments, and joint capsules. Whether effects on
purinergic signalling contribute to these effects is not yet
clear.
The substrate specificity of the E-NPP family is not
restricted to nucleotides. Besides phosphodiester bonds,
phosphonate esters, and sulfate–phosphate bonds, phospho-
lipids have recently been identified as substrates of NPP2,
extending the function of this NPP to regulation of some
receptors of the endothelial differentiation gene family, and
hence to the control of cell motility.
Aberrant expression of E-NPP-family members has been
observed in a number of disease states. However, the
physiological mechanisms of E-NPP action are still unclear.
In particular we know little concerning their physiological
substrates ‘in vivo’. The mechanisms and the signal trans-
duction cascades resulting in an aberrant E-NPP expression
are poorly documented. There is a need for more studies that
examine causal links rather than mere correlations, but
proving causality is difficult.
Research should also focus on the expression pattern of
E-NPPs in specific cell types, the identification of the
physiological substrates, elucidation of the signal transduc-
tion cascades that regulate their expression, and on the
mechanisms that are affected by changes in expression.
Progress would be greatly accelerated by the availability
of a panel of monoclonal antibodies specific for each E-NPP
protein. A similar panel of antibodies specific for each type
of purinergic receptor would allow detailed histological
studies using double labeling of single cells. This would
probably result in the clarification of much uncertainty.
The recent exciting discovery of lysophospholipase activ-
ity for NPP2 raises many important questions. Is this activity
also associated with other E-NPP family members? Is there
aberrant expression of these enzymes in tumor cells? Does
this influence their tendency to invade or metastasize? In the
long term, answers to these questions may lead to novel drugs
and treatments of diseases in which E-NPPs are involved.
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